Kolmar Bnh Co. Ltd.

Analysis

Kolmar Bnh Co. Ltd. maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is localized to 1 distinct art unit and involves a distinct examiner, reflecting a concentrated effort in a highly specialized field. This arrangement suggests that the company's current patent activity is focused on a specific biotechnological innovation that falls under the jurisdiction of a single specialized group at the patent office. The use of an examiner for the pending workload ensures consistency in the examination of the company's pharmaceutical claims.

SPAINE, ROBERT FRANKLIN is the busiest examiner on record for the company, with the pending office action currently under review. As the only examiner listed, this individual's interpretation of the prior art and patentability requirements will be decisive for the company's current application. The 1 pending office action represents the entirety of the company's active prosecution docket in this data set, highlighting the importance of this specific matter. Practitioners should consider the nuances of the biotechnology sector when responding to the examiner, as the focused nature of the portfolio leaves little room for varied outcomes across different art units. This streamlined prosecution profile simplifies administrative tracking while placing a high premium on the successful resolution of the single pending action.